[HUM] Humana: Can New Medicare Advantage Members Hold the Benefit Ratio?

Humana is a US health insurer built around Medicare Advantage (MA), the private alternative to traditional Medicare, and it also runs the CenterWell pharmacy, senior primary care and home health businesses[1]. The company is scheduled to report results for the third quarter of 2026, the three months ended September 30, 2026 (2026年第三季度(截至2026年9月30日的三个月)), on 2026-11-06[2]. In the latest disclosed quarter, the second quarter of 2026, consolidated revenue was $40.867 billion, up about 26% from $32.388 billion a year earlier; GAAP EPS was $5.73, adjusted EPS was $7.61, the Insurance segment benefit ratio was 91.2%, and individual MA membership reached 6.4537 million on June 30[3][4]. On July 29 Humana guided third-quarter adjusted EPS to approximately -$1.00 and the Insurance segment benefit ratio to slightly above 94%[5], and on October 9 it affirmed full-year adjusted EPS of at least $9.00[6]; the average of 16 analysts compiled by Drillr puts third-quarter adjusted EPS at -$1.00, and the average of 12 analysts puts revenue at about $40.87 billion[7].

Three things matter most in this report. The first is whether the third-quarter Insurance segment benefit ratio lands near "slightly above 94%": the roughly 1.2 million individual MA members added in 2026 carry a higher first-year benefit ratio, third-quarter premiums are about $39 billion, and every 50 basis points of deviation moves pretax income by about $190 million, close to $1.20 per share, which is enough to change the cushion in the "at least $9" full-year outlook[5][8]. The second is whether CenterWell can extend its second-quarter profit recovery: the segment earned $466 million in operating income in the quarter, up 35.5%, and the low end of its $1.3 billion to $1.8 billion full-year guidance requires at least about $545 million more in the second half[9][8]. The third is whether parent-company cash and leverage can absorb rapid membership growth, because first-half operating cash flow of $3.22 billion came mainly from a build-up in benefits payable while full-year guidance is only $2.5 billion to $2.9 billion, and the debt-to-capitalization ratio of 42.7% on June 30 remained above the long-term target of about 40%[10][11].

Company Background and Business Structure

Humana is an insurance and health services group that depends heavily on federal health programs. It was founded in 1961, is headquartered in Louisville, Kentucky, and is led by President and CEO Jim Rechtin[1]. In 2025 about 83% of its premiums and services revenue came from federal government contracts, including about 14% from individual MA contracts in Florida, and federal and state health programs together accounted for about 93%[12].

The Insurance segment generates most of the revenue, covering individual and group MA, stand-alone prescription drug plans (PDP, including a co-branded plan with Walmart), Medicare supplement insurance, state Medicaid contracts, the TRICARE East military health contract and specialty dental and vision coverage. On June 30, 2026, Humana had 17.9122 million medical members, including 6.4537 million individual MA, 727,200 group MA and 3.9464 million stand-alone PDP members[4]. Seniors usually compare benefits and out-of-pocket costs during the October-to-December enrollment period, the Centers for Medicare & Medicaid Services (CMS) prepays risk-adjusted premiums each month, and Humana then pays hospital, physician and pharmacy claims, managing part of its membership through capitated or risk-sharing value-based contracts[13].

The CenterWell segment provides mail-order and specialty pharmacy, senior primary care and home health, and about 80% of its revenue comes from Humana's own plans and is eliminated in consolidation. In 2025 the segment had total revenue of $22.473 billion, of which $4.816 billion was external and $17.657 billion was intersegment[14]. The annual report said the primary care business operated 350 clinics serving about 491,100 patients[15], and by June 30, 2026 patients had grown to about 622,000, an increase of 130,900 or 27% from the start of the year[16]. Humana also holds a minority stake in the home health company Gentiva and has agreed to sell all or substantially all of it for about $900 million[11].

Financial History and Current Position

In fiscal 2025 Humana kept growing revenue, but profit was roughly flat. Consolidated revenue was $129.664 billion, up from $117.761 billion in 2024, and operating income was $2.704 billion[17]; net income attributable to Humana was about $1.188 billion, or $9.84 per diluted share, slightly below $9.98 in 2024[18]. The Insurance segment benefit ratio was unchanged at 90.4%, and about $1.0 billion of favorable prior-period reserve development lowered the consolidated benefit ratio by about 80 basis points[19][20]; Insurance segment operating income was about $1.7 billion and CenterWell's was $1.339 billion[21][14].

Operating cash flow in 2025 was much weaker than earnings, and membership was shrinking. Full-year operating cash flow was only $921 million compared with $2.966 billion in 2024, while cash and cash equivalents were $4.2 billion at year-end compared with $2.2 billion a year earlier[22]. Individual MA membership fell 7.3% during the year to 5.2493 million, partly because Humana deliberately exited unprofitable plans and counties[23].

In the first half of 2026 the membership rebound drove sharply higher revenue, but the benefit ratio rose with it. First-half revenue was $80.515 billion, up 24.8%, GAAP EPS was $15.55 and adjusted EPS was $17.91, close to $14.81 and $17.85 a year earlier; the Insurance segment benefit ratio was 90.3%, 160 basis points above 88.7% a year earlier, operating cash flow was $3.22 billion, parent-company cash and short-term investments were $1.59 billion on June 30, and the debt-to-capitalization ratio was 42.7%[3]. Full-year guidance calls for revenue of at least $160 billion, adjusted EPS of at least $9.00 and GAAP EPS of at least $6.52 (previously at least $8.36), and Humana reaffirmed that guidance on September 1 and October 9[8][24][6].

Operating Model

Humana's revenue is almost entirely government health program premiums, and the core equation is that individual MA premiums equal members multiplied by the monthly CMS payment per member. That payment is set by the bid Humana submits each June, risk adjustment for member health status and Star Ratings quality bonuses, so membership growth shows up in revenue immediately while changes in ratings and bids appear only in later plan years[13][25]. In the second quarter of 2026 individual MA premiums were $28.875 billion, or $1,493 per member per month, up from $1,452 a year earlier[26]. CenterWell's intersegment revenue is eliminated in consolidation, so its contribution to consolidated revenue is mainly the external portion, which was $4.816 billion in 2025[14].

Insurance segment profit equals premiums minus benefits expense and operating costs, and the benefit ratio is the most important variable. Guidance for the 2026 Insurance segment benefit ratio is 92.75% plus or minus 25 basis points, above 90.4% in 2025, because of lower 2026 Stars bonuses, a higher benefit ratio for new members and less reserve release[8][19][27]. The benefit ratio rises through the year and peaks in the third and fourth quarters after members exhaust their deductibles, so the third quarter is usually a loss, while the operating cost ratio falls as membership growth spreads fixed costs, reaching 7.1% for the Insurance segment in the second quarter[5][3]. CenterWell profit equals services revenue minus operating costs, its operating cost ratio runs at roughly 92% to 94%, and 2026 GAAP operating income guidance is $1.3 billion to $1.8 billion, while the Insurance segment is guided only to about breakeven for the year[8].

Cash follows a different logic from profit because MA premiums are collected monthly in advance and claims are paid months later. During growth periods benefits payable accumulates and operating cash flow strengthens first, then falls back as claims are settled and as the timing of CMS Part D subsidies and state payments shifts; regulated insurance subsidiaries also need regulatory approval to pay dividends to the parent[22]. Membership growth requires the parent to contribute capital to subsidiaries, and parent-company cash fell to just $111 million on March 31, 2026[28]. Humana supplements liquidity with commercial paper, subordinated debt, a $1.5 billion contingent capital facility using pre-capitalized trust securities (P-Caps) and non-core asset sales, and it limits share repurchases to offsetting dilution from employee stock compensation[11][29].

Industry and Competitive Position

Humana is the second-largest US insurer by individual MA membership, in a market with low entry barriers where members can move every year. Its main competitors are UnitedHealth, CVS's Aetna, Elevance, Centene and regional Blue Cross plans; seniors can switch plans freely during each enrollment period, and the annual report says price, meaning premiums and benefits, will remain a significant basis of competition[30]. That means a competitor's market exit or benefit change can alter both the number and the health profile of new members flowing to Humana.

Humana stands out for its heavy concentration in Medicare and its own pharmacy, clinic and home health network, which differentiates it but also magnifies its policy exposure. Owning CenterWell turns part of medical spending into services revenue inside the group, but changes in Star Ratings, CMS rates and risk-adjustment rules hit Humana harder than more diversified peers[12][13]. Humana defines "top quartile" as Stars revenue per member per month 10% above the peer median, with a peer group of Centene, CVS, Elevance, HCSC and UnitedHealth[31]. The available material lacks comparable peer benefit ratios and margins, so this comparison can cover policy exposure and business structure but cannot directly compare profitability.

Core Debates

Will the 1.2 million new individual Medicare Advantage members push the benefit ratio above guidance in the second half?

This question sets the cushion in full-year profit guidance, because individual MA premiums make up about 70% of Humana's revenue and new members carry a higher first-year benefit ratio than retained members. On June 30, 2026 individual MA membership was 6.4537 million, about 1.2 million more than the 5.2493 million at the end of 2025 and 1,224,400 or 23.4% more than a year earlier[4][32]. The first-half benefit ratio matched company guidance, at 89.4% in the first quarter against "slightly below 90%" and 91.2% in the second quarter against "slightly above 91%"[33][34]. Management said medical and pharmacy cost trends were in line with its "high single digit" assumption, with inpatient slightly favorable and the favorability concentrated among members in value-based arrangements[35].

The current numeric baselines are a second-quarter Insurance segment benefit ratio of 91.2% (89.9% a year earlier) and 90.3% for the first half, second-quarter adjusted EPS of $7.61 and $17.91 for the first half, and individual MA premiums of $1,493 per member per month[27][3][26]. The transmission runs from new members lifting premiums by about 26% year over year, while their higher benefit ratio, lower share in value-based contracts and smaller prior-period reserve releases push the benefit ratio up. In the third quarter members enter the high-cost period after deductibles are exhausted, and a 50-basis-point miss against guidance moves EPS by about $1.20, which decides whether the full-year "at least $9" holds[5][8].

What remains unresolved is why the first half came in on target. The value-based share of individual MA members fell from 68% to 64% and days in claims payable fell from 36.5 to 33.1, so an alternative reading is that first-half results partly reflect conservative pricing and reserve assumptions, and the true cost of new members will appear only once second-half claims are fully recorded[35][3]. In the third quarter, watch whether the Insurance segment benefit ratio is near "slightly above 94%", whether the full-year 92.75% plus or minus 25 basis points holds, how adjusted EPS compares with about -$1.00, and what management says about new-member costs, specialty drug trends and reserve releases[5][8]. A third-quarter benefit ratio above 94.5% driven by higher new-member utilization would shake full-year guidance; if days in claims payable keep falling while the benefit ratio stays on target, reserve assumptions are doing more of the work.

Can the return to top-quartile Star Ratings translate into better Medicare Advantage margins in 2027?

Star Ratings were the main cause of the 2026 profit decline and are also the source of a premium recovery in 2028. The sharp drop in ratings published in October 2024 reduced 2026 bonus payments, which was the main reason 2026 adjusted EPS declined[25][8]. Humana's October 9 8-K said that, based on 2027 ratings data (bonus year 2028) provided by CMS on October 8, it had exceeded its top-quartile goal, meaning Stars revenue per member per month at least 10% above the peer median; it also said part of the outperformance is one-time and will fund one-time investments and shareholder returns[31].

That revenue reaches the income statement only in 2028, while 2027 margins depend on bid pricing, the membership mix after plan exits and the cost ratio. On the second-quarter call, management said margin improvement was the first priority of its 2027 bids, that plan exits affect about 600,000 members, most of them in plans rated 3.5 stars or lower, and that it anticipates recapturing more than 40% of affected members, as in 2025[36][37]. In the second quarter the Insurance segment operating cost ratio was 7.1% and the adjusted consolidated operating cost ratio was 9.7%, each 120 basis points lower than a year earlier[35]. Management said individual MA pretax margin is on track to double in 2026 excluding Stars and set a target of a sustainable pretax margin of at least 3% in 2028, but it has not disclosed the absolute margin[29][36].

What remains unresolved is whether 2027 margin improvement comes from better profitability on the same members or mainly from shedding members and exiting plans. Watch what the third-quarter call says about 2027 enrollment, recapture from exited plans and margin progress, whether the December 10 investor update quantifies 2027 margins and the one-time 2028 Stars benefit, and whether the third-quarter adjusted consolidated operating cost ratio stays within 10.0% plus or minus 25 basis points[8]. A recapture rate below 40% or a sharp drop in 2027 membership would mean margin gains come with a smaller business, and if the ratings were changed by a CMS recalculation or litigation, the 2028 premium base would be lower than currently understood.

Can CenterWell's clinics and pharmacy keep profits growing through the v28 phase-in and integration costs?

CenterWell is the main source of 2026 profit, because the Insurance segment is guided only to about breakeven for the year while CenterWell earned $1.339 billion in operating income in 2025[14][8]. Its volume grows with Humana's membership, but its profit is also shaped by the CMS v28 risk-adjustment model, the specialty pharmacy mix and acquisition integration. In the first quarter CenterWell operating income was $289 million, down 26%, and its operating cost ratio rose to 94.5%, which Humana attributed to the final year of the v28 phase-in, a higher specialty pharmacy mix, clinics acquired in the prior fourth quarter and MaxHealth transaction costs[29].

Profit recovered clearly in the second quarter, with operating income of $466 million, up 35.5%, and an operating cost ratio of 92.4%, slightly below 92.7% a year earlier; first-half operating income was $755 million against $736 million a year earlier[9][38][3]. Measured against the low end of the $1.3 billion to $1.8 billion GAAP operating income guidance, the second half needs at least about $545 million[8]. The transmission runs from membership growth to more prescriptions and clinic patients, about 622,000 primary care patients on June 30, while the v28 phase-in, specialty pharmacy and acquisition integration push up the operating cost ratio and weigh on profit[16]. On October 13 Humana signed a new joint venture with BlackRock's HPS, under which BlackRock buys WCAS's equity stake of about $2.8 billion in the existing clinic joint ventures; the new arrangement has no put option exercisable by BlackRock, and Humana said related balance-sheet liabilities will fall significantly[39].

What remains unresolved is how much of the second-quarter improvement will last. An alternative reading is that part of the rebound reversed first-quarter timing effects, while early losses at new clinics and low specialty pharmacy margins will still weigh on the cost ratio in the second half[29]. In the third quarter, watch whether CenterWell operating income is at least about $273 million and full-year guidance is maintained, whether the operating cost ratio stays below the prior year, and how clinic patient counts and the joint venture closing progress. A cost ratio back above 94% for persistent reasons would show that v28 and specialty pharmacy pressure has not been offset; a delayed joint venture closing would leave the cash obligations of the existing put options in place, which the first-quarter call said could fall in 2027 and 2028.

Will rapid membership growth strain the parent company's cash and leverage?

More members mean more statutory capital the parent must supply to its insurance subsidiaries, and that is the funding constraint on Humana's growth. On March 31, 2026 parent-company cash and short-term investments fell to just $111 million, compared with $1.5 billion at the end of 2025[28]. Humana has limited buybacks to offsetting stock compensation dilution and in May 2026 set up a $1.5 billion P-Caps contingent capital facility[29][11].

First-half cash looks ample, but much of it reflects payment timing. Operating cash flow was $3.22 billion in the first half against $1.602 billion a year earlier, driven mainly by a $2.909 billion increase in benefits payable, while full-year guidance is only $2.5 billion to $2.9 billion, implying a net outflow in the second half[10][8]. Parent cash of $1.59 billion on June 30 included an approximately $1.05 billion Medicaid state-directed payment that settled shortly after June 30, as well as proceeds from junior subordinated notes and commercial paper[40]. The debt-to-capitalization ratio of 42.7% was 30 basis points below 43.0% on March 31 but above 40.7% a year earlier and the long-term target of about 40%; days in claims payable fell to 33.1 from 36.5 a year earlier[11][3].

What remains unresolved is whether cash holds up once second-half claims are paid and whether asset sales arrive in time. Humana treats the sale of its Gentiva minority stake (about $900 million) and the BlackRock joint venture as ways to add capital and reduce liabilities[11][39]. In the third quarter, watch nine-month operating cash flow against the $2.5 billion to $2.9 billion full-year guidance, parent cash and the debt-to-capitalization ratio on September 30, whether Gentiva proceeds have been received and whether days in claims payable keep falling. A debt-to-capitalization ratio above 43% or a draw on the P-Caps would show funding pressure beyond plan, and full-year operating cash flow below the guidance floor would narrow room for dividend and buyback growth.

Risks and Falsifiers

The first risk is policy concentration, since about 93% of premiums and services revenue comes from government health programs. In 2025 about 83% of revenue came from federal government contracts, with Florida individual MA contracts at about 14%, and changes to CMS rate notices, the risk-adjustment model, Part D design and Stars rules, as well as Stars litigation, directly change premiums and profit[12][13][25][37]. The exposed line is consolidated revenue, guided to at least $160 billion for 2026[8]. If the 2028 rate notice and risk-adjustment rules stop pressing payments down and the 2027 ratings are not recalculated or overturned in litigation, this risk eases.

The second risk is competition and enrollment-period pricing. Seniors can switch plans every year, and competitor exits or benefit changes alter the number and health profile of Humana's new members, as the higher 2026 new-member benefit ratio already shows[30]. The exposure sits in individual MA membership and the benefit ratio, with 6.4537 million individual MA members on June 30 and full-year Insurance segment benefit ratio guidance of 92.75% plus or minus 25 basis points[4][8]. If January 2027 membership shows a lower share of new members and a rising value-based share, this concern is falsified.

The third risk is that new members use more medical care and drugs than pricing assumed. New members carry a higher first-year benefit ratio and lower value-based coverage, and the second half is the seasonally heaviest period for claims[27][5]. With third-quarter premiums of about $39 billion, every 50 basis points of benefit-ratio deviation moves pretax income by about $190 million, hitting the full-year adjusted EPS guidance of at least $9.00 directly[8]. If the third-quarter benefit ratio is about 94%, full-year guidance is unchanged and the full year lands at 92.5% to 93.0% after the fourth quarter, this risk has not materialized.

The fourth risk is that 2027 plan exits and bid pricing cause more membership loss than planned, or that competitors also retrench so recaptured members differ from 2025[36][37]. The roughly 600,000 affected members represent about $10.7 billion of annualized premiums at the second-quarter rate of $1,493 per member per month, while Humana targets an individual MA pretax margin of at least 3% in 2028[26]. If January 2027 membership shows a recapture rate of at least 40% and Humana keeps the 2028 target of at least 3%, this risk is falsified.

The fifth risk sits in CenterWell, where the v28 risk model lowers risk-score-based clinic revenue, new clinics are still in early losses and specialty pharmacy carries a higher cost ratio[9][38]. Full-year GAAP operating income guidance for the segment is $1.3 billion to $1.8 billion, with $755 million earned in the first half; each 1-percentage-point rise in the operating cost ratio cuts profit by about $68 million on second-quarter revenue of $6.79 billion[8][3]. If the operating cost ratio falls year over year in the third and fourth quarters and full-year profit lands within guidance, this risk is falsified.

The sixth risk is funding, as membership growth and second-half claim settlement pull cash down, leaving the parent to keep contributing capital to subsidiaries and to rely on short-term financing and asset sales[40]. The exposure is operating cash flow and the balance sheet: full-year operating cash flow guidance is $2.5 billion to $2.9 billion against $3.22 billion already in the first half, the debt-to-capitalization ratio is 42.7% against a target of about 40%, and about $1.05 billion of the $1.59 billion parent cash on June 30 was payment timing[8][10][11]. If full-year operating cash flow lands within guidance, the year-end debt-to-capitalization ratio is below 42% and the P-Caps remain undrawn, this risk is falsified.

What to Watch Next

• New members and the benefit ratio: the third-quarter Insurance segment benefit ratio against guidance of slightly above 94% (91.2% in the second quarter, 90.3% in the first half) and adjusted EPS against about -$1.00. A ratio above 94.5% tied to new-member utilization weakens the current understanding; about 94% with unchanged full-year guidance confirms it.
• Reserve signals: days in claims payable at 33.1 (36.5 a year earlier) and the value-based share at 64% (from 68%). Further declines while the benefit ratio stays on target would suggest reserve assumptions are doing more of the work.
• Stars and 2027 margins: recapture from plan exits affecting about 600,000 members (target above 40%), 2027 enrollment and the adjusted consolidated operating cost ratio of 9.7% in the second quarter, as described on the third-quarter call and at the December investor update. Recapture below 40% or a sharp membership drop weakens the margin case.
• CenterWell profit: third-quarter operating income of at least about $273 million after $466 million in the second quarter and $755 million in the first half, the 92.4% operating cost ratio and the joint venture closing. A cost ratio back above 94% for persistent reasons weakens the case.
• Growth funding: nine-month operating cash flow against $2.5 billion to $2.9 billion guidance, parent cash, the 42.7% debt-to-capitalization ratio and Gentiva proceeds. A ratio above 43% or a P-Caps draw signals strain.

Conclusion

Humana's profit depends on individual MA membership, the benefit ratio and CenterWell's services margin, while its cash depends on the gap between premiums collected in advance and claims paid later. In the first half of 2026 about 1.2 million new individual MA members lifted revenue to $80.515 billion and the 90.3% Insurance segment benefit ratio stayed within guidance, but the Insurance segment is guided only to about breakeven for the year, CenterWell carries most of the profit, and the 42.7% debt-to-capitalization ratio sits above the long-term target[3][8]. The central unresolved relationship is whether new members' true costs surface in the third and fourth quarters and squeeze profit and cash at the same time.

On outside views, no independent interpretation published between the second-quarter report and November 4 could be checked against its original text. STAT News's October 9 analysis of Star Ratings sits behind a paywall, Zacks's October stock article could not be read in the original, and the remaining coverage consists mostly of short items on analyst actions or institutional holdings, so there is no basis here for summarizing where outside institutions agree or disagree on the benefit ratio, Stars or funding, and the assessment rests on Humana's own disclosures.

The current understanding would strengthen if the third-quarter Insurance segment benefit ratio lands at about 94%, the full-year 92.75% plus or minus 25 basis points and "at least $9" are both maintained, CenterWell's cost ratio stays below the prior year, nine-month operating cash flow is consistent with the $2.5 billion to $2.9 billion full-year guidance and the debt-to-capitalization ratio comes down[5][8]. Conversely, a benefit ratio above 94.5% attributed to new-member utilization, a CenterWell cost ratio back above 94%, or a debt-to-capitalization ratio above 43% with a P-Caps draw would show that the cost and funding needs of growth have outrun Humana's pricing and capital plans.

Sources

[1] HUM 10-K filed 2026-02-19 · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[2] Drillr earnings calendar HUM updated 2026-11-03 · 2026-11-03 · Drillr earnings calendar

[3] HUM Q2 2026 earnings release summary of results · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000047/pressrelease.htm

[4] HUM Q2 2026 earnings release membership detail · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000047/pressrelease.htm

[5] HUM Q2 2026 prepared remarks earnings seasonality · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000045/a2q2026humanaincpostedrema.htm

[6] HUM 8-K 2026-10-09 FY2026 guidance affirmation · 2026-10-09 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm

[7] Drillr analyst estimates HUM Q3 2026 retrieved 2026-11-03 · 2026-11-03 · Drillr analyst estimates (16 analysts) · https://gateway.drillr.ai/mcp/private

[8] HUM Q2 2026 earnings release FY2026 guidance · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000047/pressrelease.htm

[9] HUM Q2 2026 10-Q CenterWell segment · 2026-07-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm

[10] HUM Q2 2026 10-Q operating cash flows · 2026-07-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm

[11] HUM Q2 2026 prepared remarks capital deployment · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000045/a2q2026humanaincpostedrema.htm

[12] HUM FY2025 10-K government program concentration · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[13] HUM FY2025 10-K CMS risk adjustment · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[14] HUM FY2025 10-K CenterWell segment results · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[15] HUM FY2025 10-K primary care and home business · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[16] HUM Q2 2026 prepared remarks CenterWell primary care · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000045/a2q2026humanaincpostedrema.htm

[17] HUM FY2025 10-K consolidated statement of operations · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[18] HUM FY2025 10-K net income attributable to Humana · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[19] HUM FY2025 10-K Insurance segment benefit ratio · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[20] HUM FY2025 10-K prior-period reserve development · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[21] HUM FY2025 10-K Insurance segment income · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[22] HUM FY2025 10-K liquidity and cash flows · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[23] HUM FY2025 10-K membership and 2026 outlook · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[24] HUM 8-K 2026-09-01 guidance reaffirmation · 2026-09-01 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000052/hum-20260901.htm

[25] HUM FY2025 10-K Star Ratings risk · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[26] HUM Q2 2026 earnings release premiums PMPM detail · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000047/pressrelease.htm

[27] HUM Q2 2026 10-Q Insurance segment benefit ratio · 2026-07-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm

[28] HUM Q1 2026 10-Q parent company cash · 2026-04-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/49071/000004907126000023/hum-20260331.htm

[29] HUM Q1 2026 earnings call 2026-04-29 · 2026-04-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[30] HUM FY2025 10-K competition · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

[31] HUM 8-K 2026-10-09 BY2028 Star Ratings · 2026-10-09 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm

[32] HUM Q2 2026 10-Q Insurance segment · 2026-07-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm

[33] HUM Q1 2026 earnings release 8-K 2026-04-29 · 2026-04-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000021/hum-20260429.htm

[34] HUM Q2 2026 earnings release 8-K 2026-07-29 · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000047/pressrelease.htm

[35] HUM Q2 2026 prepared remarks key messages · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000045/a2q2026humanaincpostedrema.htm

[36] HUM Q2 2026 earnings call 2026-07-29 · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[37] HUM Q2 2026 earnings call risks and Q&A · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[38] HUM Q2 2026 10-Q CenterWell operating cost ratio · 2026-07-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm

[39] HUM 8-K 2026-10-13 BlackRock joint venture · 2026-10-13 · 8-K · https://www.sec.gov/Archives/edgar/data/49071/000004907126000060/hum-20261013.htm

[40] HUM Q2 2026 10-Q liquidity · 2026-07-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm